Takashi Kiyoizumi, MD, PhD, SM​

Mr. Takashi Kiyoizumi is a life science entrepreneur and executive with over 30 years of experience as well as a board certified plastic surgeon. As a founding President and CEO of MediciNova, he raised over $190 million in private placements and a successful IPO, within 5 years of inception. Prior to founding MediciNova, he was President and CEO of Tanabe Research Laboratories, USA (U.S. affiliate of Mitsubishi Tanabe Pharma). Since 2005, he has been an active angel investor/board member with various life science ventures in San Diego.
  • M.D. and Ph.D. from Keio University School of Medicine
  • MBA from Sloan School of Management at MIT

Yoshiharu Mizui, Ph.D.

President of Eisai Innovation, Inc. & Head of Cambridge office

Yoshiharu Mizui founded Eisai Innovation, Inc. in 2019. Prior to that he was a global head of the BD/Strategy Department in Oncology Business Group at Eisai from 2016-2019. He was also a founding member of H3 Biomedicine and lead the oncology program from 2011-2016. He has more than 20 years of experience as a discovery research biologist. He received his Ph.D. from Kyushu University.

Sadakazu Miyashita, MS

Mr. Miyashita is presently Director of Corporate Venture Investment with Eisai Co, Ltd. Prior to this, he held roles in corporate strategy with a focus on business development as well as being stationed in Andover, MA where he was head of Portfolio Management of Andover Innovation Medicines. While at Andover, he assumed executive responsibility for drug discovery research through direct collaborations with peer laboratories involved in early stage pharmaceutical development. Before that, he has 15 years of experience as a biologist in drug discovery research along with management rolls related to strategic planning in Eisai’s laboratories. Mr. Miyashita received his MS in Molecular Biology from Gifu Pharmaceutical University.

Fumitaka Mori, Ph.D.

Partner at Taiho Innovations, LLC

Mr. Mori is a senior member of Taiho Innovations, which focuses on seed to early stage investments and company creation, following 5 years of venture investments at Remiges Ventures Boston. Prior to his experience in Venture Capital firm, he has over 12 years of experience in drug discovery research, strategic research planning, research alliances and portfolio strategy at Taiho Pharmaceutical. He received his Ph.D. in Clinical Pharmaceutical Sciences from the University of Shizuoka.

Medical Devices

Sadashi Suzuki, MBA

Mr. Suzuki started his 40+ yrs career in healthcare/life sciences with Kyowa Hakko. Recently, he held a series of management positions at Japan divisions of global companies, Baxter Japan, Alcon Japan, and Affymetrix Japan (CEO), Bio-Rad Laboratories Japan (CEO),Cepheid Japan,(CEO). Currently, he is the head of the Japan office of Newton Biocapital (Belgium base VC). He has extensive experience working with Japanese regulatory authorities on securing the approval of medical devices, testing equipment, reagents and compounds.
  • MBA from Kellogg School at Northwestern Univ.

Zachary Burkett

Mr. Zachary Burkett is a Medical Device Distributor based in New Mexico who has been in the industry for 18 years. He has 30 employees spread out over the Southwest focused on Operative and Non-Operative technologies for a broad range of specialties including Spine, Neurosurgery, Orthopedics, OMF, CardioThoracic, Critical Care and Pediatrics. He gets the pleasure of seeing many people engaged in the delivery of health care that improves the lives of many and see firsthand their challenges in providing more.


  • Abdominal

David W. Dietz, MD

David W. Dietz, MD is Chief of Colorectal Surgery at University Hospitals Cleveland Medical Center, Vice President of System Surgery Quality at University Hospitals, and Professor of Surgery at Case Western Reserve University School of Medicine. He is a graduate of Jefferson Medical College and completed both General Surgery Residency and Colorectal Surgery Fellowship at Cleveland Clinic. Dr. Dietz’s main clinical interests are reoperative abdominal and pelvic surgery, redo pelvic pouch surgery, locally-advanced and recurrent rectal cancer, and continent ileostomy surgery. He is a founder and member of the Executive Committee of the National Accreditation Program for Rectal Cancer (NAPRC).


Takuma Aoyama, MBA

Mr. Aoyama is the founder of AIFAM Group, a global investment management company. AIFAM currently manages $700 million in on a discretionary basis. Mr. Aoyama is responsible for overall investment strategy across hedge funds to private equity and venture capital. Prior to founding AIFAM, Mr. Aoyama was at UBS Global Asset Management in Chicago and Long-Term Credit Bank of Japan.
  • MBA from University of Chicago

From VCs

Justin Klein, MD, JD

Justin Klein, MD, JD is a co-founder and Managing Partner at Vensana Capital. Justin was previously a partner and leader of the medical technology investing practice at NEA, one of the largest and most active venture capital firms in the world. Justin also worked at the Duke University Health System where his experience included roles in strategy, finance and operations as Duke built one of the nation’s first integrated healthcare delivery systems. Justin currently serves as a member of the Board of Directors of the Medical Device Manufacturers Association and that of AdvaMed Accel, where he is the Chair of its MedTech Investment Working Group. Justin graduated with an AB in Economics, a BS in Biological Anthropology & Anatomy, and a Minor in Chemistry from Duke University. He also concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School.

Marc Martin-Casas, PhD

Marc joined Illumina Accelerator in 2019, where he manages seed investments and venture development in the genomic and precision medicine spaces. Previously, Marc led Biotech Connection – Bay Area, an incorporated nonprofit that accelerates innovation and development for biotech startups and big pharma by bringing together academic scientists, entrepreneurs, and investors. Prior to that, Marc was on the investment team at Lam Research Capital, where he sourced and performed diligence on life science investment opportunities. Marc earned his Ph.D. in Computational Biology from the University of California, Berkeley, where he focused on the development of novel tools to characterize, model, and predict heterogeneous behavior in cell populations and other complex biochemical systems.